See All Slides - tctmd.com

Slides

Presentation TCT 2015

Time to Revise Treatment Recommendations: Go Distal and Into the Branches

Presenter: Juan F. Granada, Michael Joner, Justin E. Davies

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

Presenter: John A. Bittl, E. Magnus Ohman, David P. Lee

October 11, 2015

Presentation TCT 2015

Germany Presents: The Diabetic Patient German Registry

Presenter: George D. Dangas, Eric Van Belle, Jens Wiebe

October 11, 2015

Presentation TCT 2015

What Are the Indications for TAVR in 2015? According to the EU and US Guidelines

Presenter: Martin B. Leon, Neil E. Moat, Alec S. Vahanian

October 11, 2015

Presentation TCT 2015

Exercise-Induced MR: Prognosis and Practicality

Presenter: Robert J. Siegel, Neil J. Weissman, Luc A Pierard

October 11, 2015

Presentation TCT 2015

Guiding DES Implantation for LMCA (and Bifurcation) Lesions: Sizing, Avoiding Complications, Predictors of Events, and Evidence for Improved Outcomes

Presenter: Carlo Di Mario, John McB. Hodgson, Jose M. de la Torre Hernandez

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Propensity-Matched Analysis: Advantages and Pitfalls (TRANSLATE and PROMETHEUS)

Presenter: Stuart J. Pocock, Jan Tijssen, Usman Baber

October 11, 2015

Presentation TCT 2015

BRS Results to Date: Imaging, Randomized Trials, and Anticipation of ABSORB III

Presenter: Thomas H. Maloney, David G. Rizik

October 11, 2015

Advertisement

Slides

Time to Revise Treatment Recommendations: Go Distal and Into the Branches

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Debate: What Is the Ideal Duration of DAPT After DES? Longer Is Better (for Most)!

Germany Presents: The Diabetic Patient German Registry

What Are the Indications for TAVR in 2015? According to the EU and US Guidelines

Exercise-Induced MR: Prognosis and Practicality

Guiding DES Implantation for LMCA (and Bifurcation) Lesions: Sizing, Avoiding Complications, Predictors of Events, and Evidence for Improved Outcomes

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Propensity-Matched Analysis: Advantages and Pitfalls (TRANSLATE and PROMETHEUS)

BRS Results to Date: Imaging, Randomized Trials, and Anticipation of ABSORB III

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content